Back to today’s briefing

Story perspectives

FDA Panel Questions SSRI Safety in Pregnant Women

8/1/2025

50 5

Summary

Story summary

An FDA panel has sparked controversy by questioning the safety of SSRIs during pregnancy, contradicting the prevailing medical consensus. Experts warn that untreated depression poses significant risks, such as suicide and preterm birth. They strongly advocate for SSRIs as a crucial treatment option, emphasizing the importance of mental health support for expectant mothers.

1 of 1

Story summary

An FDA panel has sparked controversy by questioning the safety of SSRIs during pregnancy, contradicting the prevailing medical consensus. Experts warn that untreated depression poses significant risks, such as suicide and preterm birth. They strongly advocate for SSRIs as a crucial treatment option, emphasizing the importance of mental health support for expectant mothers.